Transdermal Prescription Pain Products to Reach $9.2B by 2015

The incidence of several types of chronic and acute pain will increase significantly over the next few years, driving growth in transdermal pain products to reach $9.2 billion in 2015, according to a study by Greystone Research Associates.

According to George Perros, Greystone Research Managing Director, evolution in pain management guidelines and a better appreciation for pain-associated morbidity by clinicians are making pain management more essential for patients. Greystone's study, "Transdermal Pain Management to 2015," analyses commercial transdermal prescription drug products and development-stage candidates, as well as examining key factors influencing market demand and shaping growth prospects.

Read the Greystone Research Associates press release on transdermal pain products.



Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast